IP Library Granted Patent US 7,053,181
Granted Patent B2
US 7,053,181 · App. 10/790,396 · Granted May 30, 2006

Canine and feline B7-2 proteins, compositions and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,181
App. No.
10/790,396
Granted
May 30, 2006
Kind
B2
Abstract

The present invention relates to B7 proteins; to B7 nucleic acid molecules, including those that encode such B7 proteins; to antibodies raised against such B7 proteins; and to therapeutic compounds that regulate B7 function. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.

Claims (10)

1. An isolated protein encoded by a nucleic acid molecule comprising a nucleic acid sequence at least about 95% identical to a nucleic acid sequence selected from SEQ ID NO:9 or SEQ ID NO:19, wherein said protein is capable of binding a CTLA4 or CD28 protein or is capable of co-stimulating T-cells.

2. The isolated protein of claim 1 , wherein said protein is encoded by a nucleic acid molecule comprising a nucleic acid sequenced selected from SEQ ID NO:9 or SEQ ID NO:19.

3. The isolated protein of claim 1 , wherein said protein is encoded by a nucleic acid molecule consisting of SEQ ID NO:9 or SEQ ID NO:19.

4. A therapeutic composition comprising the isolated protein of claim 1 , wherein said composition, when administered to a canid, regulates T-cell mediated immune responses in said canid.

5. The therapeutic composition of claim 4 , wherein said composition comprises a component selected from an excipient, an adjuvant or a carrier.

6. An isolated protein comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17, wherein said isolated protein is capable of binding a CTLA4 or CD28 protein or is capable of co-stimulating T-cells.

7. The isolated protein of claim 6 , wherein said protein comprises an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17.

8. The isolated protein of claim 6 , wherein said protein consists of an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17.

9. A therapeutic composition comprising the isolated protein of claim 6 , wherein said composition, when administered to a canid, regulates T-cell mediated immune responses in said canid.

10. The therapeutic composition of claim 9 , wherein said composition comprises a component selected from an excipient, an adjuvant or a carrier.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Dec 14, 2023
From: JPMORGAN CHASE BANK, N.A.
To: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
Reel/Frame 066012/0887 →
SECURITY INTEREST Recorded Oct 24, 2017
From: HESKA CORPORATION; DIAMOND ANIMAL HEALTH, INC.; HESKA IMAGING, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 044636/0972 →